T‐cell modulation by cyclophosphamide for tumour therapy

Citations Over TimeTop 11% of 2018 papers

Abstract

The power of T cells for cancer treatment has been demonstrated by the success of co-inhibitory receptor blockade and adoptive T-cell immunotherapies. These treatments are highly successful for certain cancers, but are often personalized, expensive and associated with harmful side effects. Other T-cell-modulating drugs may provide additional means of improving immune responses to tumours without these disadvantages. Conventional chemotherapeutic drugs are traditionally used to target cancers directly; however, it is clear that some also have significant immune-modulating effects that can be harnessed to target tumours. Cyclophosphamide is one such drug; used at lower doses than in mainstream chemotherapy, it can perturb immune homeostasis, tipping the balance towards generation of anti-tumour T-cell responses and control of cancer growth. This review discusses its growing reputation as an immune-modulator whose multiple effects synergize with the microbiota to tip the balance towards tumour immunity offering widespread benefits as a safe, and relatively inexpensive component of cancer immunotherapy.

Related Papers

• → Wegener' granulomatosis(1975)104 cited
• → USE OF CYCLOPHOSPHAMIDE AND ENHANCING SERUM TO SUPPRESS RENAL ALLOGRAFT REJECTION IN THE RAT(1979)13 cited
• [Gow-Gates block for beginners].(1990)
• → Effect of Selective Blockade of α2C-Adrenoceptors on Cardiac Activity in Growing Rats(2015)1 cited
• → Effect of Paclitaxel on Antitumor Activity of Cyclophosphamide: Study on Two Transplanted Tumors in Mice(2015)1 cited